Sfoglia per AUTORE
NAGLIERI E
Collezione AOU San Luigi di Orbassano

  

Items : 4

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). in Clinical Medicine Insights. Oncology / Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollectio

2021
AOU San Luigi di Orbassano

Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A;

Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) in Journal of Clinical Oncology

2020
ASL Cuneo 2
AOU San Luigi di Orbassano

Vitale MG; Zucali PA; Milella M; Santoni M; Procopio G; Ortega C; Naglieri E; Massari F; Fornarini G; Di Lorenzo G; Chiuri VE; Calabro F; Fantinel E; Buttigliero C; Bracarda S; Bonomi L; Bersanelli M; Basso U; Atzori F; Iacovelli R;

Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study in Journal of Clinical Oncology

2020
AOU San Luigi di Orbassano

Iacovelli R; Buti S; Buttigliero C; De Vivo R; Caserta C; Ferraú F; Galli L; Martelli V; Masini C; Mattioli R; Merler S; Milesi L; Naglieri E; Ricotta R; Rizzo M; Sacco C; Santini D; Tambaro R; Verri E; Santoni M;

Seuencing chemotherapy and immune checkpoint inhibitors C in metastatic urothelial carcinoma UC: Meet-Uro1 study in Journal of Clinical Oncology

2019
AOU San Luigi di Orbassano

Bandini M; Farè E; Raggi D; De Giorgi U; Banna GL; Basso U; Losanno T; Bersanelli M; Buti S; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Ficorella C; Caffo O; Naglieri E; Pederzoli F; Pignata S; Necchi A;